Literature DB >> 29298781

High-Dimensional Profiling of Tumor-Specific Immune Responses: Asking T Cells about What They "See" in Cancer.

Evan W Newell1, Etienne Becht2.   

Abstract

The foundations of basic T-cell immunology and an understanding of the roles for T cells in controlling cancer have led to the remarkable yet inconsistent success of cancer immunotherapy. Because of these advances in cancer treatment, the need is urgent for biomarkers that can predict the efficacy of these treatments and for new therapeutic strategies for cases where currently available approaches are ineffective. Although our ability to profile heterogeneous cell populations in human blood or tissue samples has vastly improved in the past decade, identifying the cell subsets relevant to diseases, and to cancer particularly, remains a challenge. Given strong evidence for the implication of T cells specific for tumor-expressed antigens in various forms of effective immunotherapy, here, we focus on the utility, challenges, and techniques for the identification and profiling of these important cells. We review recent techniques that allow identifying and profiling of tumor-specific T cells. As these methods improve, we can expect more rapid progress in the rational design of novel cancer biomarkers and therapies based on antigen-specific T cells. Cancer Immunol Res; 6(1); 2-9. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29298781     DOI: 10.1158/2326-6066.CIR-17-0519

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  5 in total

1.  Partial absence of PD-1 expression by tumor-infiltrating EBV-specific CD8+ T cells in EBV-driven lymphoepithelioma-like carcinoma.

Authors:  Yannick Simoni; Etienne Becht; Shamin Li; Chiew Yee Loh; Joe Poh Sheng Yeong; Tony Kiat Hon Lim; Angela Takano; Daniel Shao Weng Tan; Evan W Newell
Journal:  Clin Transl Immunology       Date:  2020-09-09

2.  Topography of cancer-associated immune cells in human solid tumors.

Authors:  Jakob Nikolas Kather; Meggy Suarez-Carmona; Pornpimol Charoentong; Cleo-Aron Weis; Daniela Hirsch; Peter Bankhead; Marcel Horning; Dyke Ferber; Ivan Kel; Esther Herpel; Sarah Schott; Inka Zörnig; Jochen Utikal; Alexander Marx; Timo Gaiser; Herrmann Brenner; Jenny Chang-Claude; Michael Hoffmeister; Dirk Jäger; Niels Halama
Journal:  Elife       Date:  2018-09-04       Impact factor: 8.140

3.  SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.

Authors:  Lisa H Butterfield; Mary L Disis; Bernard A Fox; David R Kaufman; Samir N Khleif; Ena Wang
Journal:  J Immunother Cancer       Date:  2018-12-04       Impact factor: 13.751

Review 4.  High-dimensional immune-profiling in cancer: implications for immunotherapy.

Authors:  Samuel Chuah; Valerie Chew
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

5.  Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3+ and CD8+ T cell density and predict prognosis in hepatocellular carcinoma.

Authors:  Lorenzo Nicolè; Tiziana Sanavia; Rocco Cappellesso; Valeria Maffeis; Jun Akiba; Akihiko Kawahara; Yoshiki Naito; Claudia Maria Radu; Paolo Simioni; Davide Serafin; Giuliana Cortese; Maria Guido; Giacomo Zanus; Hirohisa Yano; Ambrogio Fassina
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.